Indiana manufacturer to construct facility for radioligand production
As companies both large and small are continuing to place bets on radioligand therapies, the manufacturing industry is expanding to accommodate the rising interest.
Indiana-based SpectronRx is planning to construct a new facility for producing actinium-225, which has yet to win FDA approval. SpectronRx has secured more than 10 acres in Bunker Hill, IN, a town halfway between Indianapolis and South Bend. The square footage of the facility has not been finalized, according to the company, but it will aim to produce Ac-225 for use in clinical trials and commercial supply of cancer-fighting therapies.
According to SpectronRx the company is investing millions of dollars in the project, putting put estimates north of $20 million, with plans to hire 25 new employees. The company said it has applied for state economic development assistance to complete the project.
However, while the company is pushing forward with Ac-225 production, the compound isn’t widely used now.
“Although there’s currently no (FDA)-approved treatment using Ac-225, it’s showing great promise when it comes to the treatment of certain types of cancer, including prostate, breast, colon, brain, and neuroendocrine,” said John Zehner, CEO of SpectronRx in a statement.
In an email to Endpoints News, SprectronRx president Anwer Rizvi said that using Ac-225 is showing great promise for treating certain types of cancer, including prostate, breast, colon, brain and neuroendocrine.
“But unfortunately, there is a limited supply of Ac-225, with only small amounts of it being produced by various government entities. This limits the ability of pharma companies to perform the R&D needed to advance the use of this crucial radionuclide. And once treatments are approved, supplies will become even more limited without better production, that’s why SpectronRx is building this new facility,” he said.
Other companies have been bullish on manufacturing the compound, especially in the Hoosier state.
Earlier this year, biomanufacturer Point received actinium-225 from the DOE’s Isotope Program to support its early-stage pipeline and in-house manufacturing of lutetium-177, a radioactive medicine that binds itself to tumor cells at its new 80,000-square-foot site in Indiana that Point billed as one of the largest radioligand facilities in the world.